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Abstrak 
Kadar kegagalan trombolisis dengan streptokinase adalah tinggi di kalangan 
pesakit serangan jantung walaupun harganya lebih murah dan lebih luas 
dipergunakan. Kriteria ECG yang menggunakan lebih daripada 50°/o 
pengurangan ketinggian segmen ST di lead infarct yang paling teruk adalah 
sensitif dan spesifik dalam menjangka aliran TIM I 3. 
Objektif utama kajian ini adalah untuk menentukan kadar kegagalan 
trombolisis dengan streptokinase menggunakan kriteria ECG di Hospital 
Universiti Sains Malaysia (HUSM). Objektif kedua adalah untuk menentukan 
sama ada kegagalan trombolisis dengan streptokinase mempunyai hubungan 
dengan pembolehubah tak bersandar, parameter rawatan dan parameter 
kekerapan sindrom akut koronari dan kadar kematian selepas satu tahun. 
Sejumlah 192 pesakit terlibat dalam kajian kohort retrospektif ini. Sejumlah 
109 (56.8°/o) pesakit gagal trombolisis dengan streptokinase. Terdapat 7 
pembolehubah dalam analisis univariate yang menunjukkan hubungan dengan 
kegagalan trombolisis dengan streptokinase. lni termasuklah lokasi anterior Ml 
(p<0.001 ), masa simtom-ke-jarum yang lebih lama (p=0.01 ), masa pintu-ke-
jarum yang lebih lama (min 114 ± 82.9 minit, p=0.03), sejarah hipertensi 
(p=0.04), kadar denyutan nadi yang lebih tinggi (min 79.3 ± 18.3 denyutan per 
minit, p=0.01), tekanan sistolik yang lebih tinggi (min 136.7 ± 28.9 mmHg, 
xiii 
p=0.02) dan tekanan diastolik yang lebih tinggi (min 83.8 ± 20.9 mmHg, 
p=0.003). Manakala, terdapat 5 pembolehubah dalam analisis multivariate yang 
menunjukkan hubungan dengan kegagalan trombolisis dengan streptokinase. I ni 
termasuk lokasi anterior Ml (p<0.001; OR 0.07, 95%> Cl 0.03- 0.16), masa pintu-
ke-jarum yang lebih lama (p=0.02; OR 1.01, 95°/o Cl 1.00 - 1.02), sejarah 
kencing manis (p=0.03; OR 3.13, 95% Cl 1.3 - 8.69), sejarah hipertensi (p=0.08; 
OR 2.06, 95% Cl 0.92 - 4.60) dan jumlah set darah putih yang lebih tinggi 
(p=0.03; OR 1.12, 95% Cl 1.01 - 1.24). Selain itu, analisis univariate juga 
menunjukkan bahawa kekerapan sindrom akut koronari (p=0.02; OR kasar 2.49, 
95% Cl 1.16 - 5.32) dan kadar kematian selepas satu tahun yang lebih tinggi 
(p=0.04; OR kasar 7.61, 95°/o Cl 0.95 - 61.24) adalah berkaitan dengan 
kegagalan streptokinase sebagai agen trombolisis di kalangan pesakit serangan 
jantung. 
Keputusan kajian ini menunjukkan bahawa streptokinase mempunyai kadar 
kegagalan trombolisis yang tinggi dengan menggunakan kriteria ECG di Hospital 
Universiti Sains Malaysia (HUSM). Terdapat 5 pembolehubah yang menunjukkan 
hubungan erat dengan kegagalan trombolisis dengan streptokinase. lni 
termasuklah lokasi anterior Ml, masa pintu-ke-jarum yang lebih lama, sejarah 
kencing manis, sejarah hipertensi dan jumlah sel darah putih yang lebih tinggi. 
Pesakit dengan pembolehubah-pembolehubah ini boleh dirujuk lebih awal untuk 
strategi reperfusi yang lain termasuklah tPA, PCI dan CABG. 
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Abstract 
Streptokinase has high thrombolysis failure rate despite being cheap and widely 
used in acute myocardial infarction. Electrocardiogram criteria using more than 
50% reduction in ST elevation in the worst infarct lead predicted TIMI Ill flow with 
good sensitivity and specificity. 
The primary objective of this study was to determine the failure rate of 
thrombolysis with streptokinase in acute myocardial infarction using 
electrocardiogram criteria in Hospital Universiti Sains Malaysia (HUSM). The 
secondary objective was to compare the association between independent 
variables, treatment and outcome parameters with failure of thrombolysis with 
streptokinase. 
A total of 192 subjects were recruited into this retrospective cohort 
observational study. 109 patients (56.8%) has failed thrombolysis with 
streptokinase. Seven variables were significantly associated with thrombolysis 
failure using streptokinase in a univariate analysis including anterior location of 
myocardial infarct (p<0.001 ), longer symptom-to-needle time (p=0.01 ), longer 
door-to-needle time (mean 114 ± 82.9 min, p=0.03), history of hypertension 
(p=0.04), higher heart rate (mean 79.3 ± 18.3 beats per min, p=0.01 ), higher 
systolic blood pressure (mean 136.7 + 28.9 mmHg, p=0.02) and higher diastolic 
XV 
blood pressure (mean 83.8 .± 20.9 mmHg, p=0.003). Five variables were 
associated with streptokinase failure as thrombolytic agent in multiple logistic 
regression analysis (backward stepwise method) including anterior location of 
myocardial infarct (p<0.001; OR 0.07, 95% Cl 0.03 - 0.16), longer door-to-needle 
time (p=0.02; OR 1.01, 95% Cl 1.00 - 1.02), diabetes mellitus (p=0.03; OR 3.13, 
95% Cl 1.13 - 8.69), hypertension (p=0.08; OR 2.06, 95°/o Cl 0.92 - 4.60) and 
high total white cell count (p=0.03; OR 1.12, 950fc, Cl 1.01 - 1.24). Both recurrent 
acute coronary syndrome (p=0.02; crude OR 2.49, 95o/o Cl 1.16 - 5.32) and 
death after one year (p= 0.04; crude OR 7.61, 95°/o Cl 0.95 - 61.24) were 
associated with increase in the rate of thrombolysis failure with streptokinase in 
univariate analysis. 
In conclusion, the result of this study has shown that streptokinase has higher 
failure rate of thrombolysis in acute myocardial infarction using electrocardiogram 
criteria in HUSM. History of diabetes mellitus, history of hypertension, anterior 
location of myocardial infarction, longer door-to-needle time and high total white 
cell count were highly predictive of increase in the rate of thrombolysis failure 
using streptokinase. This group of patients may benefit from other early 
reperfusion strategy including tissue plasminogen activators (tPA), PCI or CABG. 
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Chapter 1 
1.0 Introduction 
Cardiovascular disease is the commonest cause of death in our government 
hospitals accounting for 24.5o/o of all deaths for the year 1998 alone. Coronary 
heart disease accounts for a majority of these deaths (Kementerian Kesihatan 
Malaysia 1990-1998). 
Acute myocardial infarct is death of cardiac muscle following acute 
coronary occlusion due to fissuring of atherosclerotic plaques. Thrombolytic 
therapy use is aimed at achieving reperfusion in infarct related artery to 
salvage myocardium, improve remodeling, electrical stability, potential to 
provide collaterals in the event of reinfarction in other territory, preserving left 
ventricular function and reduce mortality. 
Landmark studies including GUST0-1 and ISIS-2 have shown convincing 
benefits of thrombolysis and provide groundwork for current therapeutic 
practice. A review by Fibrinolytic Therapy Trialists' (FIT) Group has shown 
that thrombolysis prevents 20 - 30 deaths per 1000 patients with 25°/o 
reduction in mortality (Fibrinolytic Therapy Trialists (FIT) Collaborative Group, 
1994). However 90 minutes arterial patency rate after streptokinase is only 
achieved in 50 - 60o/o and TIMI-3 flow from angiographic study is only 
achieved in 30°/o of patients (GUSTO investigators, 1993). 
The open-artery hypothesis suggests that reestablishing a patent infarct 
related artery (IRA) with normal antegrade flow salvages stunned myocardial 
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tissue, preserves left ventricular mechanical function and positively influences 
clinical outcomes including long term survival (Braunwald E, 1989). This 
hypothesis forms the basis for streptokinase use to achieve TIMI-3 flow in 
infarct -related artery. 
Coronary angiography is the gold standard to determine artery patency 
after reperfusion but it is expensive, invasive and not always available early. 
Therefore bedside non-invasive markers are more attractive option. Among 
them, ECG criteria has good predictive value and sensitivity. It is also easily 
available and cheap. Other parameters used include resolution of chest pain 
and peaking of cardiac enzymes including troponin T, myoglobin and creatine 
kinase. However, chest pain resolution can be subjective since most patients 
would have received analgesic. Wherelse cardiac enzymes are not always 
available, results are often delayed and can be expensive causing difficulties 
in making decision for early alternative reperfusion strategies. 
A paper by Sutton et al has shown that less than 50o/o resolution of ST 
segment elevation in the worst infarct lead had sensitivity of 81 o/o, specificity 
of 88°/o and positive predictive value of 87°/o to predict less than TIMI-3 flow. 
ST elevation is measured 80 milliseconds after J point in ECG taken within 
60-90min after given streptokinase (Sutton AGC et al., 2000). 
Failure of thrombolysis with streptokinase is associated with factors 
including age, sex, race, location of myocardial infarction, "symptom-to-
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needle" time, "door-to-needle" time, current smoking, diabetes, hypertension 
and high total white count (Conor FL et al., 1998). 
My study aims to determine the failure rate of streptokinase as 
thrombolytic agent and its association with various independent variables as 
mentioned above. This may help us to predict earlier use of other reperfusion 
strategies including tPA, PTCA or CABG. 
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1.1 Thrombolytic Therapy 
1.1.1 Physiology of thrombolysis 
A blood clot or thrombus consists of blood cells occluded in a matrix of protein 
fibrin. Thrombolysis or fibrinolysis is enzyme-mediated dissolution of fibrin clot 
with plasmin, a trypsin-like serine protease. It is produced after proteolytic 
cleavage of inactive plasminogen in circulation mediated by various 
plasminogen activators e.g. tissue type (tPA) and urokinase type (uPA). The 
fibrinolytic activity is also modulated by inhibitors of plasminogen activators 
(e.g. plasminogen activator inhibitor-1 (PAI-1), a fast-acting inhibitor of tPA 
and uPA) and plasmin (e.g. alpha1-antiplasmin, alpha2-macroglobulin) 
Recombinant forms of normal human plasminogen activators tPA and uP A 
are used in clinical intervention. Another commonly used agent is 
Streptokinase (sPA), a bacterial protein that does not occur naturally in 
human circulation. Their therapeutic action is via the activation of blood 
plasminogen to the clot dissolving plasmin. Unlike tPA or uPA, which are 
proteases, streptokinase possesses no enzymatic activity. Streptokinase 
acquires its plasminogen activating property by complexing with circulatory 
plasminogen or plasmin and the resulting high affinity 1:1 stoichiometric 
complex is a high-specificity protease that proteolytically activates other 
plasminogen molecules to plasmin (Castellino FJ, 1981). 
Patients with non-ST elevation myocardial infarction and unstable angina 
do not benefit from thrombolysis. There are several reasons. Firstly, 
angiographic study has shown that the culprit artery is not occluded in 60-85°/0 
4 
of cases (TIMI lilA investigators, 1993). Secondly, the non-occluding 
thrombus is platelet-rich which does not respond to thrombolytic therapy 
compared to AMI which is fibrin-rich. Lastly, microvascular perfusion is 
reduced in NSTEMI/UA and this is due to embolization rather than epicardial 
artery occlusion as in STEM I. 
Patients with cardiogenic shock also respond poorly probably because of 
poor penetration of thrombolytic agent into occlusive thrombus and lack of 
adequate coronary perfusion pressure in setting of hypotension which is 
necessary to maintain vessel patency (ljaz A. Khan and Ramesh M. Gowda, 
2003). 
1.1.2 Historical perspective 
Before 1980, the management of patients with acute myocardial infarction 
was centered around pharmacologic therapy directed toward managing 
arrhythmias and attempting to limit the size of the evolving infarct. Although 
these efforts were partially effective, the morbidity and mortality from AMI 
remained high. Thrombolytic agents were first used for the treatment of acute 
myocardial infarct in 1958 and gained wide acceptance in 1980s after several 
prospective, randomized, controlled trials showed a clear mortality benefit 
(ljaz AK et al, 2003). 
Direct intracoronary administration of fibrinolysin was first reported from 
Russia in 1976 which subsequently led to reperfusion era that initially used 
intracoronary streptokinase in a few centers in the late 1970s and early 1980s 
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(Rentrop P and Blanke H, 1981 ). However initial therapy using intracoronary 
thrombolytic therapy was impractical as it required emergency coronary 
angiography and hence restricted to a few hospitals with facilities and trained 
personnel for coronary angiography. These problems subsequently led to the 
development of systemic administration of streptokinase for fibrinolysis. 
The first landmark trial from Italy (Gruppo Italiano per lo Studio della 
Streptochinasi nell'infarto Miocardico (GISSI), 1986) has established the life-
saving strategy of early intravenous thrombolytic therapy in acute myocardial 
infarction. US Food and Drug Administration (FDA) approval was granted in 
late 1987 following this study. 
6 
1.2 Comparing Plasminogen Activators 
Different thrombolytic agent differs in their efficacy and fibrin selectivity. Even 
with the same thrombolytic agent, different doses, different administration 
regimens and concomitant use of adjunctive agents can cause significant 
variations to the patency rates (ljaz A. Khan and Ramesh M. Gowda, 2003). 
1.2.1 First generation agents 
There are 3 agents in this group : streptokinase, urokinase and anisoylated 
plasminogen streptokinase activator complex (APSAC). These agents are not 
fibrin specific and they convert plasminogen to plasmin. There is a constant 
equilibrium between circulating plasminogen and plasminogen in the 
thrombus. Eventually there will be depletion of plasminogen which reduces 
clot lysis (known as "plasminogen steal"). Also both streptokinase and APSAC 
are immunogenic and can result in drug resistance, fever, hypotension and 
allergic reactions. 
Urokinase is a two chain serine protease isolated from human kidney 
cells, so allergic effects are minimal. It has a half-life of 15-20 minutes and 
metabolized in the liver. Current interest is limited because, like streptokinase, 
it lacks fibrin specificity and like tPA, it is very expensive (3x of Streptokinase). 
In addition production is limited due to problems in manufacturing process. 
Anistreplase (APSAC) has longer half life than streptokinase so can be used 
as bolus but it is as antigenic as streptokinase with similar side-effects profile 
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and mortality benefits. Although the cost is higher, it does not have any 
compelling advantage. Hence it is not very commonly prescribed. 
1.2.2 Second generation agents 
Tissue plasminogen activator (tPA) or alteplase (Activase in United States 
and actilyse in Europe) is the most widely used fibrin selective agent in this 
group. It is a glycoprotein with 527 amino acids, produced using recombinant 
technology. 
The risk of intracranial hemorrhage is higher than streptokinase (0. 7 
versus 0.5%). Other limitations include a procoagulant effect with resistance 
to recanalization in 15-40°/o. Only half reach TIMI 3 flow on angiographic 
study. Reocclusion rates may reach up to 10% at 1 week and 25% at 12 
weeks and time to reperfusion delayed up to 45 minutes. Heparin is usually 
co-administered for at least 48 hours due to its short half-life and to avoid 
reocclusion. The accelerated dose regimen using not more than 100mg of tPA 
over 90minutes produces more rapid thrombolysis than the standard 3 hours 
infusion of tPA. 
1.2.3 Third generation agents 
They are derived from modifications of basic tPA structure and as a result, the 
half-life is lengthened. There is an increased resistance to plasma protease 
inhibitors and there is more selective binding to fibrin. Among these agents 
include reteplase, lanoteplase, tenecteplase and staphylokinase. 
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Table 1.1 Characteristics of US-FDA Approved Thrombolytic Agents 
Characteristics 
Molecular weight 
Half life(min) 
Dose/time 
BolusAdm 
Metabolism 
Allergic reaction 
Hypotension 
Early Heparin 
Fibrin Selective 
Systemic Fibrinogen 
Fibrinogen 
breakdown 
Plasminogen binding 
TIMI 3 flow (0/o) 
90min patency (o/o) 
Intracerebral bleed 
Mortality rates(%) 
Abbreviations : 
STK = Streptokinase 
APSAC = Anistreplase 
TN Kase = Tenecteplase 
STK 
47,000 
23 
1.5MU 
No 
Hepatic 
1-4% 
Yes 
?Yes 
No 
Marked 
4+ 
Indirect 
32 
50 
0.5 
7.3 
APSAC 
131,000 
100 
30mg 
Yes 
Hepatic 
-
Yes 
?Yes 
No 
Marked 
-
Indirect 
43 
65 
0.6 
10.5 
9 
Alteplase Reteplase TNKase 
70,000 39,000 70,000 
<5 13-16 20-24 
100mg 10+10U 0.5mg/Kg 
No Yes Yes 
Hepatic - -
<0.2°/o No <1% 
No No No 
Yes Yes Yes 
Yes Yes Yes 
Mild Moderate -
1-2+ Unknown 4-15 
Direct Direct Direct 
54 60 66 
75 80 75 
0.8 0.9 -
7.2 7.5 
1.3 Streptokinase 
Streptokinase is an extracellular enzyme produced by various strains of beta-
hemolytic streptococci. It is a single-chain polypeptide with a molar mass of 
47 kDa and made up of 414 amino acid residues. The protein exhibits its 
maximum activity at pH of 7.5 and it does not contain cysteine, cystine, 
phosphorus, conjugated carbohydrates and lipids (Banerjee A et al, 2004). 
1.3.1 Structure and Mechanism of action 
Different groups of streptococci produce streptokinase which differs in 
structural domains (i.e., alpha, beta, gamma) and functional properties. The 
exact mechanism on how streptokinase activates plasminogen remains to be 
elucidated. It is known that multiple domains are involved in interaction with 
plasminogen. The C-terminal of streptokinase is involved in plasminogen 
substrate recognition and activation and the Asp41 - His48 region is 
important in binding to plasminogen. The coiled region of streptokinase-
gamma domain is said to be essential for plasminogen activation and similarly 
beta domain is involved in forming the streptokinase-plasminogen complex 
responsible for activating the plasminogen. The first 59 amino acid residues or 
N-terminal portion has important functional roles. Without the N-terminal, 
streptokinase has unstable secondary structures and thus reduces the activity 
of remaining amino acid residues (Banerjee et al, 2004). 
1.3.2 Production of Streptokinase 
Streptokinase producing streptococci were first identified in 187 4 by Bill roth in 
exudates of infected wounds. Later the blood of patients with scarlet fever 
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was shown to contain similar streptococci. In ~ 933, Lancefield used serologic 
distinctions to differentiate the beta-hemolytic streptococci into groups A to 0. 
Most streptokinase was obtained from streptococci of Lancefield groups A, C 
and G. The group C is preferred as they lack erythrogenic toxins. The C strain 
of Streptococcus equisimilis H46A isolated from human source in 1945 has 
been widely used and it yielded the most active streptokinase. Subsequently, 
the streptokinase gene from Streptococcus equisimilis was sequenced by 
Malke et al (1985) and since then considerable information exists for 
effectively and safely producing recombinant streptokinase in non-pathogenic 
bacteria. 
In order to produce streptokinase, streptococci need to grow and 
proliferate in suitable complex and rich media (known as fermentation). Since 
Bernheimer et al (1942), many modifications have been made on his original 
media in order to achieve high biomass growth. Christensen (1945) has used 
medium containing peptone, phosphate salts, glucose, biotin, riboflavin, 
tryptophan, glutamine and nucleic acids (thiamine, adenine and uracil) to 
produce streptokinase from S.equisimilis H46A. This medium contains less 
glutamine (25%) compared to Bernheimer's media and the low glucose 
content allow growth without generation of excessive acid. Continous culture 
has a higher productivity compared to batch culture. In addition batch culture 
has a rather extended lag phase followed by a short period of exponential 
growth. 
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Other mediums used include Baewald et al (1975) containing yeast 
autolyzate or corn steep liquor as nitrogen source; brain-heart infusion (BH I) 
by Malke and Ferreti (1984) and Suh et al (1984); chemically defined media 
(COM) which requires small inocula and comparable doubling time to complex 
media (McCoy et al 1991 ). Other methods include use of mutant 
Streptococcus and recombinant production which has far higher yield 
compared to culture method. 
After fermentation, streptokinase must be assayed and quantified before 
they can be extracted. Assay of streptokinase rely on its ability to activate 
plasminogen (deriving from human, chimpanzee, monkey, cat, dog, and 
rabbit) to plasmin which then hydrolyzes an indicator substrate including fibrin 
clot, casein, other proteins and various synthetic esters (e.g. lysine methyl 
ester, lysine ethyl ester etc). Christensen (1949) devised the first quantitative 
method using fibrin clot as indicator substrate. Other methods include solid 
phase chromogenic assay for plasmin reported by Kulisek et al 1989; 
enzyme-linked immunosorbent assay (ELISA) for antibodies against 
streptokinase developed by Leornadi et al (1983) and enzyme immunoassay 
for streptokinase by Shemanova et al (1995). The latter method was more 
sensitive and requires only micro-quantities of blood serum. 
The final step will be recovery and purification of streptokinase using 
various chromatography methods as described by De Renzo et al (1967), 
Tomar (1968), Taylor and Botts (1968), Einarsson et al (1979) and Perez et al 
(1998). Commercial production of streptokinase requires biosafety 
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consideration to process workers as the streptokinase protein can be 
immunogenic and streptococci can be potentially pathogenic. 
1.3.3 Safety of thrombolysis 
Bleeding (minor or major) is the major complication. However most bleeding is 
relatively minor. Most serious bleeding episodes occur in patients who 
undergo invasive procedures. Three quarters of bleeding episodes occur at 
vascular puncture sites (Sane DC and Califf RM, 1989). Intracranial 
hemorrhage is the most serious complication and its frequency depends on 
the regimen used and patient characteristics. It is more common with 
lanoteplase than with alteplase or tenecteplase and less frequent with 
streptokinase (Maggioni AP and Franzosi MG, 1992). The clinical variables 
known to predict increased risk of bleeding: patients over 65 years, female 
sex, low body weight {<70kg), hypertension on presentation and use of tPA 
compared to streptokinase. 
There are reports of early mortality in the first 24 hours especially among 
elderly. The mechanism for early mortality include increased risk of 
myocardial rupture (especially elderly), fatal intracranial hemorrhage, and 
inadequate myocardial perfusion resulting in pump failure. However, excess 
mortality (10.5°/o of total deaths) is offset by the deaths prevented by 
thrombolysis (30 per 1 000 patients presented within 6 hours) as shown in a 
meta-analysis (Fibrinolytic Therapy Trialists (FTT) Collaborative Group, 1994). 
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Previous exposure to streptococci in the past one year can produce 
antibody-mediated resistance to streptokinase and anistreplase in most 
cases. Other rare complications include splenic rupture, aortic dissection and 
cholesterol embolization. 
1.3.4 Precautions and Contraindications 
Preferably more than one peripheral venous access should be available and 
arterial punctures are avoided. Ideally procedures such as pulmonary artery 
catheters or temporary transvenous catheter placements, if needed, should 
be performed in an expeditious fashion prior to administration of thrombolytic 
agents. Subclavian catheter should be avoided because it is difficult to control 
any excessive bleeding. 
Thrombolytic agents are considered as category C drugs in pregnancy. 
There are no animal studies and it is not known whether streptokinase can 
cause fetal harm when administered to the pregnant woman or whether it can 
affect reproduction capacity. It is also not known whether these agents are 
secreted in human milk (ljaz AK et al, 2003). 
Major recent streptococcal infection as mentioned above can cause 
resistance to streptokinase because of anti-streptococcal antibodies. 
Hypertension is a less contraindication against streptokinase than against 
alteplase. Gentamicin sensitivity is a specific exclusion criteria for use of 
alteplase (as gentamicin is used in the alteplase preparation). 
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Table 1.2 : Contra indications for Fibrinolvsis in ST -elevation Mvocardial Infarct 
(Adapted from ACC/AHA auidelines 2004) 
Absolute 
Contra indications 
Relative 
Contra indications 
1. Any prior intracranial hemorrhage 
2. Known structural cerebral vascular lesion 
3. Known malignant intracranial neoplasm 
4. Ischemic stroke within 3 months 
5. Suspected aortic dissection 
6. Active bleeding or bleeding diathesis including 
menstruation 
7. Significant closed-head or facial trauma within 3 
months 
1. History of chronic severe poorly controlled 
hypertension 
2. SBP > 180mmHg or DBP > 110mmHg 
3. History of prior ischemic stroke greater than 3 
months, dementia or known pathology not covered 
above 
4. Traumatic or prolonged (>10 minutes) CPR or major 
surgery less than 3 weeks 
5. Recent (2 - 4 weeks) internal bleeding 
6. Non-compressible vascular puncture 
7. Pregnancy 
8. Active peptic ulcer 
9. Current use of anti-coagulants 
10. Prior exposure or allergic reaction (more than 5 days) 
to streptokinase/anistreplase 
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1.4 Acute Myocardial Infarct 
1.4.1 Definition 
Acute myocardial infarction (AMI) is defined as necrosis of heart muscle due 
to inadequate blood supply following an acute coronary artery occlusion. This 
occlusion is usually due to plaque rupture or fissuring with superimposed 
thrombosis. Rarely this may result from coronary spasm, coronary embolism 
or vasculitis (Fallon JT, 1996). 
1.4.2 Diagnosis 
Diagnosis of acute myocardial infarct according to revised World Health 
Organization (WHO) definition in 1979 was based on the presence of at least 
two of the following three criteria (W.H.O., 1979): 
1. Clinical history of ischemic type of chest discomfort 
2. Evolutionary changes on serially obtained ECG tracings 
3. A rise and fall in serum cardiac markers 
However, this criteria has its limitations. Many patients who have STEMI 
are asymptomatic, a substantial number have an ECG with only nonspecific 
changes or may even be normal, and some patients have normal serum CK-
MB but elevated troponins. Therefore these patients may be wrongly 
classified as unstable angina. As a result of these limitations, the European 
Society of Cardiology (ESC) and the American College of Cardiology (ACC) 
has proposed a new definition in year 2000 for acute, evolving or recent 
myocardial infarct. This new definition incorporated sensitive and specific 
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markers including troponins and newer imaging techniques that are able to 
detect small infarcts that would not have considered AMI previously. 
Either one of the following criteria would satisfy diagnosis of AMI (Alpert 
JS et al., 2000) : 
Or 
1. Typical rise and gradual fall (troponin) or more rapid rise and 
fall (CK-MB) of biochemical markers of myocardial necrosis with 
at least one of the following : 
a. Ischemic symptoms 
b. Development of pathological Q waves on ECG 
c. ECG changes indicative of ischemia 
d. Coronary artery intervention (e.g., coronary angioplasty) 
2. Pathological findings of an acute myocardial infarct 
1.4.3 Chest Pain 
Chest pain is the single most important symptom in AMI. It is usually 
retrosternal, usually lasts at least 20 minutes. It can occur at rest or with 
activity. The pain is usually central or in the left chest and may radiate to jaw 
or down the left upper limb. It may be crushing, pressing or burning in nature 
but severity of pain is variable. Occasionally the pain may occur in epigastric 
region and therefore may be misinterpreted as heartburn or indigestion. 
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Other associated symptoms include dyspnea, nausea and vomiting, 
palpitations, weakness, dizziness, lightheadedness and syncope. Diabetics, 
elderly and females may not present with typical ischemic type of chest pain. 
In a local study, among 887 patients in Hospital Selayang; race, male sex, 
sudden onset of persistent crushing pain, associated with sweating and a 
history of diabetes mellitus were found to be significant predictors of AMI. 
Pain that is relieved by other means and history of heart disease on treatment 
are important predictors of a diagnosis other than AMI. The specificity is high 
at 80.5% (Bulgibaa AM and Razazb M, 2005). 
Approximately two thirds of patients describe the new onset of angina or a 
change in their chest pain pattern in the month preceding infarction. However 
in approximately one fourth of patients, myocardial infarction is associated 
with only mild symptoms or no symptom of chest pain at all. 
1.4.4 Electrocardiogram in diagnosis of AMI 
Electrocardiogram (ECG) can demonstrate evolutionary changes of acute 
myocardial infarction starting from hyperacute changes of tall peaked T -wave 
which indicates localized hyperkalemia, ST segment elevation followed by Q-
wave over several hours to days, return of ST segment to isoelectric baseline 
and T wave inversion. 
Diagnosis of STEMI requires presence of ST segment elevation and 
pathological Q-waves. Criteria for ST segment elevation at J point are ~0.2mV 
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in leads V1, V2 or V3 and ~0.1 mV in other leads and should be present in 2 or 
more contiguous leads. J point is described as the first turning point in ST 
segment. 
Q-wave is the first negative deflection of QRS complex and it is 
pathological when duration is more than 0.04 seconds. Criteria for AMI would 
be presence of any Q-wave in leads V1-V3 or Q-wave greater than or equal to 
30ms (0.03s) in leads I, II, aVL, aVF, V4-V6 and must be present in any 2 
contiguous leads and be greater than or equal1mm in depth (W.H.O., 1979). 
Localization of infarct depends on the presence of both Q waves and ST 
elevation in certain contiguous leads. Anterior infarct has ECG changes over 
leads I, aVL and from V1 till V6. Inferior infarct has ECG changes over leads 
II, Ill and aVF. Right ventricular infarct has ECG changes over V4R and V5R. 
If ST segment elevation is present along with typical chest pain, the 
likelihood that patient has acute myocardial infarct is greater than 90°/o. Other 
non-specific findings include ST segment depression, T wave inversion and 
bundle branch block but are less specific. Half of the patients with myocardial 
infarct may not have ST elevation. 
1.4.5 Cardiac enzymes in diagnosis of AMI 
Injury to cardiac myocytes will release intracellular enzymes into the blood 
allowing their detection. Traditionally creatinine kinase (CK) and its 
isoenzyme, creatinine kinase-myocardial band (CK-MB) were used as early 
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marker for diagnosis of acute myocardial infarct. Rapid assays were 
developed allowing faster availability of results within 30-60 minutes. 
Drawbacks to its use include its lack of specificity for cardiac muscles and 
time required for CK-MB to rise. Both CK and CK-MB require at least 3 hours 
of profound ischemia in order to rise above normal. In addition, in patients 
who have only partial obstruction or presence of extensive collaterals can 
further delay the release of these enzymes. 
In order to overcome these limitations, other blood tests were developed 
including myoglobin and troponins. Myoglobin is a low molecular weight heme 
protein in cardiac muscle and it is rapidly released from infarcted myocardium 
compared to CK-MB but it is also found in skeletal muscle making it less 
specific. 
Troponin is a more specific marker, rises rapidly after infarction and has 
been proven in previous clinical trials to predict subsequent cardiac events. 
Since troponin is relatively new and expensive, it is not readily available in 
many coronary care units including our centre till recently. 
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1.5 Markers of Patency after Thrombolysis 
1.5.1 Electrocardiogram criteria using ST segment resolution 
Prognosis of AMI treated with thrombolysis is strongly related to achievement 
of early patency of culprit coronary artery and this was well documented in 
clinical trials in which coronary angiography has been performed shortly after 
thrombolytic therapy. 
Various electrocardiogram markers have been proposed by various 
investigators as predictors of outcome but not all can adequately delineate 
risk strata for patients with AMI in the early hours after thrombolysis other than 
ST segment resolution. There are many criteria for ST segment resolution. 
Among them include ST segment reduction > 70%, 30 to 70o/o and less than 
30°/o. Some investigators advocate criteria of less than 50°/o and some 
suggest complete resolution of ST segment as the most sensitive marker. 
Review of few studies have shown that ST segment resolution of 50°/o 
correlates best with early patency after thrombolysis with good sensitivity and 
specificity. This is supported from papers by Sutton (2000) and Syed MA 
(2004) as described below. 
In the study by Sutton (2000), which is a prospective cohort study 
conducted in a regional cardiothoracic unit involving 100 patients with acute 
myocardial infarct to determine whether simple, readily applicable ECG 
criteria will allow early prediction of inadequate ( < TIM I 3) flow in the infarct 
related vessel in patients receiving thrombolytic treatment; and to determine 
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the success of streptokinase in achieving adequate antegrade flow in the 
infarct related vessel two hours after starting treatment. The ECG test that 
performed best among the six criteria was < 50o/o resolution of the ST 
segment elevation in the worst lead and no accelerated idioventricular rhythm. 
This had a sensitivity of 81 °/o, specificity of 88o/o, positive predictive value of 
87°/o, negative predictive value of 83%, and overall accuracy of 85o/o. (Sutton 
AGC et al., 2000) 
Syed MA (2004) assessed the usefulness of a single lead ST resolution at 
90 minutes after thrombolysis compared with the sum of ST resolution in 
predicting TIMI 3 flow, using prospectively collected data from the Limitation 
of Myocardial Injury Following Thrombolysis in Acute Myocardial Infarction 
(LIMIT-AMI) study. All patients had electrocardiogram recorded at 
presentation and 90 minutes and a coronary angiogram 90 minutes after 
thrombolysis. Infarct artery patency was assessed in 238 patients with 4 
different ST resolution criteria: single lead ST resolution > or =50o/o and > or 
=70o/o and sum ST resolution > or =50°/o and > or =70°/o. The most sensitive 
criteria for TIMI grade 3 flow was single lead ST resolution > or =50o/o 
(sensitivity rate, 70%; specificity rate, 54o/o}, whereas sum ST resolution > or 
=70°/o was most the specific criteria (sensitivity rate, 45°/o; specificity rate, 
79°/o}. The author proposed that single lead ST-resolution > or =50o/o as the 
optimal ECG indicator for successful reperfusion 90 minutes after 
thrombolysis (Syed MA et al., 2004). 
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In another study, the prognostic power of noninvasive markers of coronary 
artery reperfusion was evaluated in 967 patients with acute myocardial 
infarction who were treated with intravenous streptokinase. The following 
criteria were chosen : resolution of chest pain and ST -segment resolution 
>50°/o at 90 minutes, abrupt creatinine kinase rise before 12 hours, and T-
wave inversion in infarct-related electrocardiographic leads within the first 24 
hours after thrombolysis. Each reperfusion marker was associated with 
improved outcome but multivariate analysis showed that ST segment 
resolution was significantly and independently associated with low in-hospital 
mortality rate (Ramon C et al., 1999). 
This classic and often quoted study by Schroeder (1995) has assessed 
prospectively the prognostic power of early ST segment resolution in a cohort 
of 1909 German patients in a substudy of The International Joint Efficacy 
Comparison of Thrombolytics (INJECT) trial which compared mortality in 
6,010 patients randomized to receive either reteplase or streptokinase. The 
three groups of ST segment resolution were defined as complete (;:::70°/o), 
partial (70°/o to 30°/o) and no resolution (<30% to >0%). Among 1,398 patients 
presenting <6 h, the 35 day mortality rate for complete, partial and no ST 
segment resolution was 2.5%, 4.3°/o and 17.5°/o, respectively (p < 0.0001). 
When baseline characteristics were included, no ST segment resolution was 
the most powerful independent predictor of 35-day mortality. The author 
concluded that partial ST segment resolution predicts larger infarct areas, but 
early mortality is relatively low (Schroeder R et al., 1995). 
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In another earlier report by Saran RK et al (1990), a reduction of greater 
than 25% in ST segment elevation 3 hours after thrombolytic treatment and 
angiographic study in 83 patients had a sensitivity of 97°/o but a specificity of 
only 43°/o in predicting a patent infarct artery or preservation of left ventricular 
function. 
As a conclusion, newer trials using prospective design have shown that 
electrocardiogram criteria using ST segment resolution of < 50°/o is a sensitive 
early marker of patency after thrombolysis. 
1.5.2 Other electrocardiogram markers of patency 
Other investigators have attempted to evaluate other electrocardiogram 
markers but were thought to be too complex and too technical to be used in 
clinical practice. Some of these studies may be flawed in designs and others 
which could not demonstrate its superiority over ST segment resolution as 
early marker of patency. 
Another potential marker would beT wave inversion in the infarct related 
ECG leads but it is limited by its late occurrence after 24 hours. For example, 
(Matetzky S et al., 1994) found that T wave inversion was associated with 
TIMI Ill flow in a series of 100 patients after thrombolysis within 36- 48hours. 
Similarly, (Castro P et al., 1992) has compared T wave inversion with other 
reperfusion indexes and found that it was the most significant predictor of 
patency after thrombolysis at 24 hours. 
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